A Randomized, Phase II/III Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion
Categories (click each to see list of all clinical trials associated with that category): GI (ONC), Pancreatic Cancer Center of Excellence - PCCE (ONC)
Current Status: Not open
Phase: II/III
Principal Investigator: Klute, Kelsey
Contact Information:
Monica Davis
mondavis@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT07076121?term=NCT07076121&rank=1#participation-criteria
Summary
Primary objectives:
To evaluate PFS of BMS-986504 in combination with nab-p/gem vs placebo + nab-p/gem in participants with untreated metastatic PDAC with homozygous MTAP deletion
Secondary objectives:
To evaluate the efficacy of BMS-986504 in combination with nab-p/gem vs placebo + nab-p/gem in participants with untreated metastatic PDAC with homozygous MTAP deletion